Trospium Chloride Capsule, Extended Release
Product Images NDC 70436-174

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Trospium Chloride (NDC 70436-174). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Slate Run Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

60mg-30ct (60mg 30ct)

60mg-30ct (60mg 30ct)
Drug facts label for Trospium Chloride extended-release capsules 60 mg. The label states dosage form, strength, storage instructions, child-resistant packaging, and handling precautions. It includes the manufacturer and distributor information from Slate Run Pharmaceuticals, LLC, and the product NDC 70436-174-04. The label reminds users to see the package for full prescribing information and notes the package contains 30 capsules.*
FDA Label Image

Api-structure (Api Structure)

Api-structure (Api Structure)
Chemical structure of trosium chloride showing its molecular arrangement including a quaternary ammonium salt with a chloride ion and ester functional groups.*
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A line chart showing plasma concentration (ng/mL) of Trospium Chloride Extended-Release Capsules 60 mg over time. The x-axis represents hours post-dose from 0 to 24 hours, and the y-axis shows plasma concentration from 0 to 4 ng/mL. The graph illustrates a peak plasma concentration around 4 to 6 hours post-dose, followed by a gradual decline up to 24 hours.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A line graph comparing the average change over 12 weeks of treatment between placebo and Trospium chloride extended-release capsules. The x-axis represents the week of treatment (0, 1, 4, 12), and the y-axis shows the average change with standard error. Two lines depict data from placebo (N=300) and Trospium chloride extended-release capsules (N=292), with statistical significance values indicated at weeks 1, 4, and 12.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A line chart comparing average change over 12 weeks between placebo and trospium chloride extended-release capsules groups. The x-axis represents weeks of treatment (0, 1, 4, 12), and the y-axis shows average change with standard error. The trospium chloride group consistently shows greater average reduction, with p-values indicated at weeks 1, 4, and 12 demonstrating statistical significance.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
A line graph comparing the average change over weeks of treatment between placebo and Trospium chloride extended-release capsules (N=267 each). The y-axis shows average change with standard error, and the x-axis shows weeks 0, 1, 4, and 12. The graph includes p-values indicating statistical significance at weeks 1, 4, and 12.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
A line graph comparing average change over weeks of treatment between placebo and Trospium chloride extended-release capsules (60 mg) in a clinical study. The x-axis shows weeks of treatment (0, 1, 4, 12) and the y-axis shows average change with standard error bars. Data points indicate statistically significant differences (p<0.001) favoring Trospium chloride at each time point.*
FDA Label Image

Image-a-2 (Image A 2)

Image-a-2 (Image A 2)
TROSPIUM CHLORIDE 60 mg extended-release capsules label showing the capsule external appearance. The capsule is oblong, half yellow and half orange, with black imprint "174" on the yellow side. This oral prescription drug is manufactured by Slate Run Pharmaceuticals, LLC.*
FDA Label Image

Image-a (Image A)

Image-a (Image A)
Packaging label of TROSPIUM CHLORIDE 60 mg extended-release capsules by Slate Run Pharmaceuticals, LLC. The bottle contains 30 capsules, with the product name and dosage strength clearly visible on the front label. The label includes directions for oral administration.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.